PHVS

Pharvaris N.V. [PHVS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHVS Stock Summary

Top 10 Correlated ETFs

PHVS

Top 10 Correlated Stocks

PHVS

In the News

PHVS Financial details

Company Rating
-
Market Cap
894.76M
Income
-84.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-11.31
Forward P/E
-
PEG
-0.98
P/S
-
P/B
6.26
P/C
-
P/FCF
-10.66
Quick Ratio
9.85
Current Ratio
10.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.04
EPS next Y
-
EPS next Q
-
EPS this Y
60.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.94%
-
-
-
-
SMA20
-1.57%
SMA50
1.27%
SMA100
18.93%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-56%
ROC
-0.48%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.93-33.0
52W High
-22.97%
52W Low
+263.14%
RSI
41.97
Rel Volume
0.89
Avg Volume
110.2K
Volume
98.29K
Perf Week
-5.15%
Perf Month
-8.53%
Perf Quarter
0.24%
Perf Half Y
9.33%
-
-
-
-
Beta
-3.113
-
-
Volatility
0.6%, 0.83%
Prev Close
-3.64%
Price
25.42
Change
-5.64%

Something similar

Top by Market Cap
TSLA
GOOG
ABEC.DE
APC.DE
BRYN.DE
Top Correlated ETFs
NLR
BATT
FORH
URA
GDMA
Top Correlated Stocks
FSY.TO
CVVUF
B
GRIN
TLRY
Similar Market Cap
HMSO.L
PABCX
GCG.TO
AIC
NPACY

Company Profile

Healthcare Biotechnology
  • Volume Average 110.2K
  • Market Capitalization 894.76M
  • Employee 70
  • CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.
  • Headquarters Leiden,NL
  • IPO Date 2021-02-05
  • Website https://pharvaris.com

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.